NO20084119L - Anvendelse av CK2-inhibitor til behandling og kjemostabilisering av tilbakevendende tumorer overfor anti-kreft-medikamenter - Google Patents
Anvendelse av CK2-inhibitor til behandling og kjemostabilisering av tilbakevendende tumorer overfor anti-kreft-medikamenterInfo
- Publication number
- NO20084119L NO20084119L NO20084119A NO20084119A NO20084119L NO 20084119 L NO20084119 L NO 20084119L NO 20084119 A NO20084119 A NO 20084119A NO 20084119 A NO20084119 A NO 20084119A NO 20084119 L NO20084119 L NO 20084119L
- Authority
- NO
- Norway
- Prior art keywords
- pharmaceutical combination
- peptide
- inhibitor
- cancer treatment
- treatment
- Prior art date
Links
- 239000002246 antineoplastic agent Substances 0.000 title abstract 6
- 206010028980 Neoplasm Diseases 0.000 title abstract 4
- 229940041181 antineoplastic drug Drugs 0.000 title abstract 2
- 229940122360 Casein kinase 2 inhibitor Drugs 0.000 title 1
- 230000000306 recurrent effect Effects 0.000 title 1
- 102000052052 Casein Kinase II Human genes 0.000 abstract 2
- 108010010919 Casein Kinase II Proteins 0.000 abstract 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 abstract 2
- -1 Vinca alkaloids Chemical compound 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 108010042445 cell-binding peptide P-15 Proteins 0.000 abstract 2
- 239000000824 cytostatic agent Substances 0.000 abstract 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 abstract 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 abstract 1
- 239000005517 L01XE01 - Imatinib Substances 0.000 abstract 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 abstract 1
- 229930012538 Paclitaxel Natural products 0.000 abstract 1
- 229940122803 Vinca alkaloid Drugs 0.000 abstract 1
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 abstract 1
- 230000003034 chemosensitisation Effects 0.000 abstract 1
- 229940044683 chemotherapy drug Drugs 0.000 abstract 1
- 229960004316 cisplatin Drugs 0.000 abstract 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 abstract 1
- 229960004397 cyclophosphamide Drugs 0.000 abstract 1
- 229940127089 cytotoxic agent Drugs 0.000 abstract 1
- 229960004679 doxorubicin Drugs 0.000 abstract 1
- 229960005420 etoposide Drugs 0.000 abstract 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 abstract 1
- 229960002949 fluorouracil Drugs 0.000 abstract 1
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 abstract 1
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 abstract 1
- 229960002411 imatinib Drugs 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 229940084651 iressa Drugs 0.000 abstract 1
- 231100000053 low toxicity Toxicity 0.000 abstract 1
- 229960001592 paclitaxel Drugs 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 abstract 1
- 229940099039 velcade Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Inorganic Chemistry (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Foreliggende oppfinnelse angår en farmasøytisk kombinasjon som inneholder en Caseinkinase 2 (CK2) peptidinhibitor (navngitt P15) sammen med standard kjemoterapeutiske legemidler anvendt ved kreftbehandling og som administreres sammen, separat eller sekvensielt. De kjemoterapeutiske legemidlene inkluderer cisplatin, taxol, alkaloider fra Vinca, 5-fluoruracil, doxorubicin, cyklofosfamid, etoposid, mitomicin C, imatinib, iressa og velcade (vortezomib). Synergien mellom P15-peptidet og antikreftlegemidlene gir en effektiv konsentrasjon av hvert cytostatisk legemiddel i kombinasjonen som er fra 10 til 100 ganger lavere enn den for hvert cytostatisk legemiddel alene. Den farmasøytiske kombinasjonen beskrevet ifølge oppfinnelsen fremviser lav toksisitet sammenlignet med den som rapporteres fra antikreftterapeutiske midler og derfor representerer den en viktig fordel ved dens anvendelse ved kreftbehandling. Videre fører den sekvensielle administrasjonen av denne farmasøytiske kombinasjonen gjennom forhåndsbehandling med P15-peptidet til en kjemosensibilisering av refraktære tumorer ovenfor antikreftterapetutiske midler.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CU20060049A CU23511B6 (es) | 2006-02-28 | 2006-02-28 | Combinación farmacéutica para el tratamiento y/o quimiosensibilización de tumores refractarios a drogas anticancerígenas |
| PCT/CU2007/000010 WO2007098719A1 (es) | 2006-02-28 | 2007-02-28 | Combinación farmaceutica para el tratamiento y/o quimiosensibilización de tumores refractarios a drogas anticancerígenas |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20084119L true NO20084119L (no) | 2008-11-25 |
| NO341904B1 NO341904B1 (no) | 2018-02-19 |
Family
ID=40134932
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20084119A NO341904B1 (no) | 2006-02-28 | 2008-09-29 | Farmasøytisk kombinasjon for simultan, separat eller sekvensiell administrasjon |
Country Status (22)
| Country | Link |
|---|---|
| US (3) | US8871725B2 (no) |
| EP (1) | EP1997506B8 (no) |
| JP (2) | JP5733880B2 (no) |
| KR (1) | KR101454866B1 (no) |
| CN (1) | CN101432012B (no) |
| AR (1) | AR059645A1 (no) |
| AU (1) | AU2007219572B2 (no) |
| BR (1) | BRPI0708307B1 (no) |
| CA (1) | CA2642943C (no) |
| CL (1) | CL2015001086A1 (no) |
| CU (1) | CU23511B6 (no) |
| CY (1) | CY1114686T1 (no) |
| DO (1) | DOP2007000040A (no) |
| MX (1) | MX2008011141A (no) |
| MY (1) | MY150135A (no) |
| NO (1) | NO341904B1 (no) |
| PE (1) | PE20081191A1 (no) |
| PL (1) | PL1997506T3 (no) |
| RU (1) | RU2396974C2 (no) |
| UY (1) | UY30175A1 (no) |
| WO (1) | WO2007098719A1 (no) |
| ZA (1) | ZA200807323B (no) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CU23511B6 (es) * | 2006-02-28 | 2010-04-13 | Biorec B V | Combinación farmacéutica para el tratamiento y/o quimiosensibilización de tumores refractarios a drogas anticancerígenas |
| GB0803352D0 (en) | 2008-02-22 | 2008-04-02 | Ntnu Technology Transfer As | Oligopeptidic compounds and uses thereof |
| US20100173013A1 (en) * | 2009-01-08 | 2010-07-08 | Denis Drygin | Treatment of neoplastic disorders using combination therapies |
| EP3866804A4 (en) | 2018-10-19 | 2022-08-03 | Senhwa Biosciences, Inc. | Combinations for immune-modulation in cancer treatment |
| CN109875998B (zh) * | 2019-01-24 | 2021-09-03 | 武汉大学 | 酰胺类生物碱在制备肿瘤化疗药物增敏剂中的应用及抗肿瘤药物组合物 |
| CN110448699B (zh) * | 2019-06-12 | 2022-03-11 | 天津医科大学 | 包含功能性多肽修饰七甲川花菁素类染料的肿瘤细胞核靶向载药纳米粒子及制备方法 |
| CU20200103A7 (es) * | 2020-12-18 | 2022-07-08 | Ct Ingenieria Genetica Biotecnologia | Péptido sintético para la inducción de inmunidad antitumoral y antiviral |
| CN114712377B (zh) * | 2022-04-26 | 2023-08-15 | 江苏师范大学 | 断血流皂苷a在制造药物中的用途 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100558356C (zh) * | 1996-10-15 | 2009-11-11 | G.D.瑟尔公司 | 应用环加氧酶-2抑制剂治疗和预防肿瘤形成的方法 |
| CU23225A1 (es) | 2001-12-20 | 2007-08-30 | Ct Ingenieria Genetica Biotech | PéPTIDOS PARA EL TRATAMIENTO DEL CáNCER ASOCIADO AL VIRUS PAPILOMA HUMANO (VPH) Y DE OTROS TUMORES EPITELIALES |
| US7351729B2 (en) * | 2002-03-08 | 2008-04-01 | Signal Pharmaceuticals, Llc | JNK inhibitors for use in combination therapy for treating or managing proliferative disorders and cancers |
| US20060014987A1 (en) * | 2003-07-07 | 2006-01-19 | Lan Huang | Synthesis of beta-elemene, intermediates thereto, analogues and uses thereof |
| US20080255132A1 (en) * | 2003-11-14 | 2008-10-16 | Eric Rowinsky | Combination Therapy Comprising the Use of Et-743 and Paclitaxel for Treating Cancer |
| MXPA06006651A (es) * | 2003-12-09 | 2006-08-11 | Gov Health & Human Serv | Metodos para suprimir una respuesta inmune o un tratamiento para un trastorno proliferativo. |
| TW200538149A (en) * | 2004-05-20 | 2005-12-01 | Telik Inc | Sensitization to another anticancer therapy and/or amelioration of a side effect of another anticancer therapy by treatment with a GST-activated anticancer compound |
| CU23511B6 (es) * | 2006-02-28 | 2010-04-13 | Biorec B V | Combinación farmacéutica para el tratamiento y/o quimiosensibilización de tumores refractarios a drogas anticancerígenas |
-
2006
- 2006-02-28 CU CU20060049A patent/CU23511B6/es active IP Right Grant
-
2007
- 2007-02-23 DO DO2007000040A patent/DOP2007000040A/es unknown
- 2007-02-27 AR ARP070100805A patent/AR059645A1/es not_active Application Discontinuation
- 2007-02-27 UY UY30175A patent/UY30175A1/es not_active Application Discontinuation
- 2007-02-28 JP JP2008556646A patent/JP5733880B2/ja active Active
- 2007-02-28 CA CA2642943A patent/CA2642943C/en active Active
- 2007-02-28 MY MYPI20083318A patent/MY150135A/en unknown
- 2007-02-28 WO PCT/CU2007/000010 patent/WO2007098719A1/es not_active Ceased
- 2007-02-28 PE PE2007000215A patent/PE20081191A1/es not_active Application Discontinuation
- 2007-02-28 PL PL07711104T patent/PL1997506T3/pl unknown
- 2007-02-28 BR BRPI0708307-6A patent/BRPI0708307B1/pt not_active IP Right Cessation
- 2007-02-28 RU RU2008138534/15A patent/RU2396974C2/ru active
- 2007-02-28 MX MX2008011141A patent/MX2008011141A/es active IP Right Grant
- 2007-02-28 EP EP07711104A patent/EP1997506B8/en active Active
- 2007-02-28 US US12/280,629 patent/US8871725B2/en active Active
- 2007-02-28 CN CN2007800152341A patent/CN101432012B/zh active Active
- 2007-02-28 KR KR1020087023587A patent/KR101454866B1/ko active Active
- 2007-02-28 AU AU2007219572A patent/AU2007219572B2/en not_active Ceased
-
2008
- 2008-08-23 ZA ZA200807323A patent/ZA200807323B/xx unknown
- 2008-09-29 NO NO20084119A patent/NO341904B1/no not_active IP Right Cessation
-
2013
- 2013-02-15 CY CY20131100142T patent/CY1114686T1/el unknown
- 2013-07-12 JP JP2013146681A patent/JP2013231065A/ja not_active Withdrawn
-
2014
- 2014-09-19 US US14/490,856 patent/US9226946B2/en active Active
- 2014-10-20 US US14/518,242 patent/US9278118B2/en active Active
-
2015
- 2015-04-24 CL CL2015001086A patent/CL2015001086A1/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20084119L (no) | Anvendelse av CK2-inhibitor til behandling og kjemostabilisering av tilbakevendende tumorer overfor anti-kreft-medikamenter | |
| ES2622559T3 (es) | Combinación terapéutica que comprende un inhibidor de cdk y un agente antineoplásico | |
| CA3167746A1 (en) | Compounds and uses thereof | |
| RU2438664C2 (ru) | Синергическая фармацевтическая комбинация для лечения рака | |
| BRPI0721626A2 (pt) | combinaÇço farmacÊutica sinergÍstica para o tratamento de cÂncer | |
| US8492397B2 (en) | Aminopyridine derivatives having Aurora A selective inhibitory action | |
| KR20100126479A (ko) | 개선된 항종양 치료법들 | |
| EP2403339B1 (en) | Combination cancer therapy with an akt inhibitor and other anticancer agents | |
| Curran et al. | Vinorelbine: a review of its use in elderly patients with advanced non-small cell lung cancer | |
| AU2005231436A1 (en) | Use of 5,10-methylene tetrahydrofolate for the treatment of cancer | |
| RU2346686C2 (ru) | Комбинации, включающие эпотилоны и антиметаболиты | |
| Li et al. | Structure and activity relationship analysis of xanthones from mangosteen: Identifying garcinone E as a potent dual EGFR and VEGFR2 inhibitor | |
| CN110520118A (zh) | 谷氨酰胺类似物的前药 | |
| KR20140056238A (ko) | 약제의 병용에 의한 암 치료 방법 | |
| EP3880207A1 (en) | Combination of a mcl-1 inhibitor and midostaurin, uses and pharmaceutical compositions thereof | |
| Ge et al. | Induced IGF-1R activation contributes to gefitinib resistance following combined treatment with paclitaxel, cisplatin and gefitinib in A549 lung cancer cells | |
| BR112015021448B1 (pt) | Uso do peptídeo gliadina no tratamento de câncer | |
| Badary et al. | Differential alteration of cisplatin cytotoxicity and myelotoxicity by the paclitaxel vehicle cremophor EL | |
| Al Khafaji et al. | Anticancer and Antioxidant Effects of Sitagliptin and Linagliptin against Lung Cancer Cell Lines (an In vitro Study). | |
| TH138873A (th) | สารรวมทางเภสัชกรรมสำหรับการบำบัดรักษา และ/หรือ เคโมเซนซิบิไลเซชันของเนื้องอกที่ดื้อต่อยาต้านมะเร็ง | |
| Mattos | Marine Natural Products as Molecular Probes to Study Cancer Cell Stress and Proteostasis | |
| Salako et al. | Screening of Amodiaquine for its in vitro Anti-cancer Activity on Breast Cancer Cell Lines-a Case Study for Drug Reprofiling | |
| JP5842367B2 (ja) | 抗癌剤増感剤 | |
| JP2007529540A5 (no) | ||
| Grossi et al. | Chemotherapy plus bevacizumab in the first-line treatment of non-small cell lung cancer: benefits, risks and limitations |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |